Taking This Popular Anti-Depressant During Pregnancy Can
Lead To Language Disorders In Offspring
By Kurtis Bright
With The Ubiquity Of Anti-Depressants Comes A Dark Side For
Pregnant Women
It’s hard to imagine who difficult being pregnant must be. The
changes wrought on a woman’s body are massive, brutal, and they must be tremendously
stressful--both physically and mentally.
All of which would go a long way to explaining why SSRIs or
selective seratonin re-uptake inhibitors are an extremely common prescription for
pregnant women; in fact they are the most common type of antidepressant
prescribed to women who are pregnant.
But a troubling new study has shown compelling evidence that
taking such drugs during pregnancy is associated with a higher risk of language
disorders for the woman’s offspring, including dyslexia.
According to the study, children of women who took SSRIs
while they were pregnant had a 37 percent higher chance of developing speech or
language disorders when compared with the offspring of women who reported
depression, but who remained unmedicated with SSRIs during their term.
However Dr. Alan Brown, study lead author was quick to quash
panic. As he explained in a CNN interview, what the numbers mean is this: if a
mother doesn’t take SSRIs during her pregnancy, her child’s risk of developing
speech disorders is about 1 percent. On the other hand, the study showed that when
a pregnant woman is on SSRIs, her offspring’s chance of developing such a
disorder rises to 1.37 percent.
That may not seem like a lot, but given the sheer population
of the world and the numbers of people on SSRIs, it makes a significant
difference, according to Dr. Brown.
“When you have relative risks that are 1.37, they're
considered to be low,” he said. “But because so many people are exposed--6
percent to 10 percent of mothers are exposed (to antidepressants) throughout
the world--it's increasing the public health burden.
“I don’t think individuals have to worry about this, but I
do think at the population level it makes a very big difference,” he added.
Published in the journal JAMA Psychiatry, Dr. Brown’s study pulled data from the
records of some 850,000 live births
between 1996 and 2010, categorizing the mothers into three groups: one group
that purchased SSRIs at least once during their pregnancy, one group that had
been diagnosed with depression but did not purchase antidepressants, and a
third that had never been diagnosed with depression nor purchased
antidepressants, assuming the purchase of antidepressants to represent women
who considered themselves to be depressed.
The study found that women who purchased SSRIs more than
once during their pregnancy demonstrated an even higher risk of speech or
language disorders in their offspring compared with the women in the other
groups.
“These disorders are quite prevalent in the population. They
cause significant impairment," Brown said, adding that dyslexia,
articulation disorders and other diagnosed language disorders can have a
“...potentially big effect on school function and later life function. It's a
significant public health issue: A lot of therapies, speech language therapies,
a lot of funds get invested. It's a large burden to society and also to
individuals.”
So it seems like a tough choice: nine months of depression
going untreated--at least with SSRIs--or imposing a lifetime of speech
disorders on your unborn child.
That can be just one more to add to the list of the
sacrifices we ask mothers to make.
###
No comments:
Post a Comment